휴미라(Humira) 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Humira Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1770910
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 184 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
휴미라 세계 시장 규모는 2024년에 104억 1,000만 달러, 2030년에는 198억 4,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR 11.32%로 성장할 것으로 예측됩니다.
류마티스 관절염, 건선성 관절염, 크론병, 궤양성 대장염, 강직성 척추염 등 자가면역질환 및 만성 염증성 질환의 유병률 증가로 인해 이 시장은 꾸준히 성장하고 있습니다. 노인 인구의 증가와 조기 진단 및 치료에 대한 인식 개선으로 휴미라(아달리무맙)와 같은 생물학적 제제의 처방 빈도가 증가하고 있습니다. 휴미라는 염증을 억제하고 장기적인 질환 관리를 개선하는 효과가 입증되어 류마티스내과, 소화기내과, 피부과 등 다양한 전문과에서 선호하는 치료제로 사용되고 있습니다. 또한, 새로운 적응증과 병용요법을 모색하는 임상시험을 통해 그 사용 범위가 넓어지고 있습니다. 주요 특허가 만료되었음에도 불구하고, 이 브랜드는 강력한 시장 입지를 유지하고 있습니다. 이는 투여 방법의 혁신, 환자 지원 프로그램, 바이오시밀러 의약품의 경쟁에 따른 영향을 줄이기 위한 전략적 라이선싱 활동 등에 힘입은 바 있습니다.
The Global Humira Market was valued at USD 10.41 Billion in 2024 and is projected to reach USD 19.84 Billion by 2030, growing at a CAGR of 11.32% during the forecast period. The market is witnessing steady growth, fueled by the increasing prevalence of autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. With a growing elderly population and improved awareness around early diagnosis and treatment, biologic therapies like Humira (adalimumab) are being prescribed more frequently. Humira's proven effectiveness in reducing inflammation and improving long-term disease management has made it a preferred treatment across various specialties, including rheumatology, gastroenterology, and dermatology. Additionally, its usage is being extended through clinical trials exploring new indications and combination therapies. Despite the expiration of key patents, the brand continues to maintain a strong market presence, aided by innovations in delivery methods, patient assistance programs, and strategic licensing efforts that help mitigate the impact of biosimilar competition.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 10.41 Billion
Market Size 2030
USD 19.84 Billion
CAGR 2025-2030
11.32%
Fastest Growing Segment
Ulcerative Colitis (UC)
Largest Market
North America
Key Market Drivers
Rising Prevalence of Autoimmune and Chronic Inflammatory Diseases
The increasing incidence of autoimmune and chronic inflammatory disorders is a primary factor driving the Global Humira Market. According to the World Health Organization, approximately 18 million people were living with rheumatoid arthritis in 2019, with a 14.1% increase in global age-standardized prevalence since 1990. In the United States alone, psoriasis affects about 3% of the adult population, totaling over 7.5 million individuals.
This expanding patient base fuels the demand for biologic treatments like Humira, especially as healthcare providers are beginning therapy earlier in the disease course to prevent long-term complications. Greater public awareness and advocacy have also contributed to earlier diagnosis and intervention, making advanced immunotherapies more integral to treatment strategies. Humira's long-standing clinical use across multiple therapeutic areas has established it as a trusted option among physicians, reinforcing its continued adoption.
Key Market Challenges
Patent Expirations and Loss of Exclusivity
One of the most significant challenges facing the Global Humira Market is the expiration of its key patents and the resulting loss of market exclusivity. AbbVie's Humira enjoyed a dominant position due to robust patent protection, but the introduction of biosimilar adalimumab products has begun to erode its market share. These biosimilars offer similar efficacy at lower prices, prompting healthcare systems-particularly in cost-sensitive regions-to encourage their use as a cost-saving measure.
As biosimilar availability expands, insurers and pharmacy benefit managers are prioritizing them over the originator drug, increasing pressure on prescribers to switch treatments. This competitive shift is changing pricing dynamics and weakening Humira's revenue potential in markets where cost containment and accessibility are key concerns.
Key Market Trends
Rising Demand for Real-World Evidence (RWE)
A growing focus on Real-World Evidence (RWE) is shaping the Global Humira Market, as stakeholders seek comprehensive data on how treatments perform outside controlled clinical trials. With the rise of biosimilars and competitive pricing, regulators, payers, and clinicians are relying more on RWE to evaluate long-term outcomes, adherence rates, patient satisfaction, and comparative effectiveness across various populations.
RWE provides valuable insights into how therapies function in real-world settings, especially for patients with multiple conditions or inconsistent treatment patterns. These insights are crucial for making informed decisions about therapy options, reimbursement policies, and value-based care initiatives, particularly as the market adapts to increasing biosimilar usage.
Key Market Players
Alvotech
Amgen Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
CELLTRION INC.
Coherus BioSciences, Inc.
Fresenius Kabi AG
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
Pfizer Inc.
Samsung Bioepis Co., Ltd.
Sandoz Inc.
Report Scope:
In this report, the Global Humira Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Humira Market, By Product:
Branded
Biosimilar
Humira Market, By Application:
Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Crohn's Disease (CD)
Ulcerative Colitis (UC)
Ankylosing Spondylitis
Others
Humira Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Humira Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Humira Market.
Available Customizations:
Global Humira Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
